Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pain block could keep hip surgery patients comfortable for days

NCT ID NCT07643792

Symptom relief Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tests whether a single injection of a slow-release painkiller (liposomal bupivacaine) into a nerve block can control pain for up to 72 hours after hip fracture surgery in older adults. The standard drug only lasts about 12 hours, often leading to more pain and opioid use. The trial will compare pain scores and opioid consumption in 148 patients aged 55 and older.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liposomal bupivacaine
What this could lead to
If it works, this could provide better pain control for up to 72 hours after hip surgery, reducing the need for opioids and lowering complication risks in older patients.
What could go wrong
This is a small, early-phase trial (148 participants) comparing two types of nerve blocks, so results may not apply broadly. The long-acting drug may not prove significantly better than the standard short-acting one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 148 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥ 18 years. * Scheduled to undergo hip replacement surgery. * Agree to receive regional nerve block and postoperative patient-controlled intravenous analgesia (PCIA). Exclusion Criteria: * Inability to communicate due to visual, auditory, language, or other reasons before surgery. * Chronic opioid dependence and long-term use of various types of analgesics (for more than 3 months). * Severe coagulation abnormalities (International Normalized Ratio \> 1.7, activated partial thromboplastin time exceeding the normal value by more than 4 seconds, platelet count \< 80 × 10⁹/L), trauma or infection at the intended puncture site, or severe low back pain. * Preoperative severe renal insufficiency (serum creatinine \> 442 μmol/L or requiring renal replacement therapy), hepatic insufficiency (Child-Pugh class C), or ASA physical status \> IV. * Known allergy to local anesthetics. * Any other condition that the investigator or attending physician deems unsuitable for participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fascia iliaca block are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hip fracture Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fascia iliaca block Hip fracture surgery Hip surgery Liposomal bupivacaine Older adults Postoperative pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.